GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » Cyclically Adjusted Price-to-FCF

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Cyclically Adjusted Price-to-FCF : (As of May. 20, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Hunan Er-Kang Pharmaceutical Co Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Hunan Er-Kang Pharmaceutical Co Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Hunan Er-Kang Pharmaceutical Co's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Er-Kang Pharmaceutical Co Cyclically Adjusted Price-to-FCF Chart

Hunan Er-Kang Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hunan Er-Kang Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hunan Er-Kang Pharmaceutical Co's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Er-Kang Pharmaceutical Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hunan Er-Kang Pharmaceutical Co's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hunan Er-Kang Pharmaceutical Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Hunan Er-Kang Pharmaceutical Co's Cyclically Adjusted Price-to-FCF falls into.



Hunan Er-Kang Pharmaceutical Co Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Hunan Er-Kang Pharmaceutical Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Hunan Er-Kang Pharmaceutical Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.02/115.2271*115.2271
=-0.020

Current CPI (Mar. 2024) = 115.2271.

Hunan Er-Kang Pharmaceutical Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.009 98.200 -0.011
201409 -0.046 98.900 -0.054
201412 -0.071 99.000 -0.083
201503 -0.075 99.900 -0.087
201506 -0.028 99.500 -0.032
201509 0.029 100.500 0.033
201512 0.087 100.600 0.100
201603 -0.402 102.200 -0.453
201606 0.040 101.400 0.045
201609 -0.073 102.400 -0.082
201612 -0.098 102.600 -0.110
201703 -0.061 103.200 -0.068
201706 0.156 103.100 0.174
201709 0.107 104.100 0.118
201712 0.007 104.500 0.008
201803 0.067 105.300 0.073
201806 -0.025 104.900 -0.027
201809 -0.065 106.600 -0.070
201812 0.035 106.500 0.038
201903 -0.066 107.700 -0.071
201906 -0.001 107.700 -0.001
201909 -0.044 109.800 -0.046
201912 0.151 111.200 0.156
202003 -0.119 112.300 -0.122
202006 -0.220 110.400 -0.230
202009 0.046 111.700 0.047
202012 0.058 111.500 0.060
202103 -0.013 112.662 -0.013
202106 -0.012 111.769 -0.012
202109 -0.023 112.215 -0.024
202112 -0.077 113.108 -0.078
202203 0.043 114.335 0.043
202206 -0.045 114.558 -0.045
202209 0.029 115.339 0.029
202212 0.025 115.116 0.025
202303 -0.086 115.116 -0.086
202306 0.063 114.558 0.063
202309 -0.073 115.339 -0.073
202312 0.054 114.781 0.054
202403 -0.020 115.227 -0.020

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Hunan Er-Kang Pharmaceutical Co  (SZSE:300267) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Hunan Er-Kang Pharmaceutical Co Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Hunan Er-Kang Pharmaceutical Co's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Business Description

Traded in Other Exchanges
N/A
Address
Kangping Road 167, National Economic and Technological Development Zone, Liuyang Changsha, Hunan, CHN, 410331
Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Headlines

No Headlines